Loading news...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Stock News Saks Global files Chapter 11: Saks Global (private) sought Chapter 11 protection, citing heavy debt from its 2024 Neiman Marcus deal and inventory st
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00. The sale was disclosed in a legal filing with the Securities and
United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Madrigal (MDGL). But which of these two companies is the best option for those looking for undervalued stocks?
Investors looking for stocks in the Medical - Drugs sector might want to consider either United Therapeutics (UTHR) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) Director Christopher Causey sold 1,000 shares of the business's stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $500.01, for a total transaction of $500,010.00. Following the transaction, the director owned 4,190 shares in the company, valued at approximately
Stock News Safe havens jump after Venezuela shock: Gold and silver surged while defense names advanced as investors reacted to the U.S. capture of Venezuela's N
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will present a company overview and update on Monday, January 12, 2026, from 1:30 to 2:10 p.m. PST, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An ar.
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $485.43, for a total value of $4,029,069.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday. The stock traded as high as $519.99 and last traded at $510.44, with a volume of 382750 shares changing hands. The stock had previously closed at $513.79. Wall Street Analysts Forecast Growth UTHR has been
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) Director Louis Sullivan sold 5,950 shares of the business's stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $512.13, for a total transaction of $3,047,173.50. The transaction was disclosed in a legal filing with the Securities and Exchange Commission,
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) Director Tommy Thompson sold 910 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $500.59, for a total transaction of $455,536.90. Following the completion of the sale, the director directly owned 8,480 shares of
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the company's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $494.72, for a total value of $1,978,880.00. Following the completion of the sale, the chief executive officer owned 130 shares in
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 3,517 shares of the firm's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $495.36, for a total transaction of $1,742,181.12. Following the completion of the sale, the chief financial officer owned 8,142 shares in
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven research firms that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the firm's stock in a transaction on Friday, December 12th. The stock was sold at an average price of $490.70, for a total value of $1,962,800.00. Following the sale, the chief executive officer directly owned 130 shares of the company's